651 related articles for article (PubMed ID: 34821965)
1. Phage therapeutics: from promises to practices and prospectives.
Bhargava K; Nath G; Bhargava A; Aseri GK; Jain N
Appl Microbiol Biotechnol; 2021 Dec; 105(24):9047-9067. PubMed ID: 34821965
[TBL] [Abstract][Full Text] [Related]
2. Phage and phage cocktails formulations.
Mani I
Prog Mol Biol Transl Sci; 2023; 200():159-169. PubMed ID: 37739554
[TBL] [Abstract][Full Text] [Related]
3. Phage Therapy in the Resistance Era: Where Do We Stand and Where Are We Going?
Luong T; Salabarria AC; Roach DR
Clin Ther; 2020 Sep; 42(9):1659-1680. PubMed ID: 32883528
[TBL] [Abstract][Full Text] [Related]
4. Phage-Antibiotic Synergy Is Driven by a Unique Combination of Antibacterial Mechanism of Action and Stoichiometry.
Gu Liu C; Green SI; Min L; Clark JR; Salazar KC; Terwilliger AL; Kaplan HB; Trautner BW; Ramig RF; Maresso AW
mBio; 2020 Aug; 11(4):. PubMed ID: 32753497
[TBL] [Abstract][Full Text] [Related]
5. Phage-based therapy against biofilm producers in gram-negative ESKAPE pathogens.
Ragupathi NKD; Muthuirulandi Sethuvel DP; Gopikrishnan M; Dwarakanathan HT; Murugan D; Biswas I; Bakthavachalam YD; Murugesan M; George Priya Doss C; Monk PN; Karunakaran E; Veeraraghavan B
Microb Pathog; 2023 May; 178():106064. PubMed ID: 36898591
[TBL] [Abstract][Full Text] [Related]
6. Bacteriophage treatment as an alternative therapy for multidrug-resistant bacteria.
Alqahtani A
Saudi Med J; 2023 Dec; 44(12):1222-1231. PubMed ID: 38016738
[TBL] [Abstract][Full Text] [Related]
7. Bacteriophage therapy against ESKAPE bacterial pathogens: Current status, strategies, challenges, and future scope.
Kulshrestha M; Tiwari M; Tiwari V
Microb Pathog; 2024 Jan; 186():106467. PubMed ID: 38036110
[TBL] [Abstract][Full Text] [Related]
8. Bacteriophage Therapeutics: A Primer for Clinicians on Phage-Antibiotic Combinations.
Morrisette T; Kebriaei R; Lev KL; Morales S; Rybak MJ
Pharmacotherapy; 2020 Feb; 40(2):153-168. PubMed ID: 31872889
[TBL] [Abstract][Full Text] [Related]
9. Inhaled Bacteriophage Therapy for Multi-Drug Resistant
Winzig F; Gandhi S; Lee A; Würstle S; Stanley GL; Capuano I; Neuringer I; Koff JL; Turner PE; Chan BK
Yale J Biol Med; 2022 Dec; 95(4):413-427. PubMed ID: 36568830
[TBL] [Abstract][Full Text] [Related]
10. Bacteriophage as a Novel Therapeutic Weapon for Killing Colistin-Resistant Multi-Drug-Resistant and Extensively Drug-Resistant Gram-Negative Bacteria.
Mousavi SM; Babakhani S; Moradi L; Karami S; Shahbandeh M; Mirshekar M; Mohebi S; Moghadam MT
Curr Microbiol; 2021 Dec; 78(12):4023-4036. PubMed ID: 34633487
[TBL] [Abstract][Full Text] [Related]
11. Associations among Antibiotic and Phage Resistance Phenotypes in Natural and Clinical
Allen RC; Pfrunder-Cardozo KR; Meinel D; Egli A; Hall AR
mBio; 2017 Oct; 8(5):. PubMed ID: 29089428
[TBL] [Abstract][Full Text] [Related]
12. Towards promising antimicrobial alternatives: The future of bacteriophage research and development in Saudi Arabia.
Alsaadi A; Imam M; Alghamdi AA; Alghoribi MF
J Infect Public Health; 2022 Dec; 15(12):1355-1362. PubMed ID: 36332378
[TBL] [Abstract][Full Text] [Related]
13. Bacteriophages and antibiotic interactions in clinical practice: what we have learned so far.
Łusiak-Szelachowska M; Międzybrodzki R; Drulis-Kawa Z; Cater K; Knežević P; Winogradow C; Amaro K; Jończyk-Matysiak E; Weber-Dąbrowska B; Rękas J; Górski A
J Biomed Sci; 2022 Mar; 29(1):23. PubMed ID: 35354477
[TBL] [Abstract][Full Text] [Related]
14. Bacteriophage genome engineering for phage therapy to combat bacterial antimicrobial resistance as an alternative to antibiotics.
Usman SS; Uba AI; Christina E
Mol Biol Rep; 2023 Aug; 50(8):7055-7067. PubMed ID: 37392288
[TBL] [Abstract][Full Text] [Related]
15. Bacteriophage therapy for inhibition of multi drug-resistant uropathogenic bacteria: a narrative review.
Chegini Z; Khoshbayan A; Vesal S; Moradabadi A; Hashemi A; Shariati A
Ann Clin Microbiol Antimicrob; 2021 Apr; 20(1):30. PubMed ID: 33902597
[TBL] [Abstract][Full Text] [Related]
16. Clinical and experimental bacteriophage studies: Recommendations for possible approaches for standing against SARS-CoV-2.
Shahin K; Zhang L; Mehraban MH; Collard JM; Hedayatkhah A; Mansoorianfar M; Soleimani-Delfan A; Wang R
Microb Pathog; 2022 Mar; 164():105442. PubMed ID: 35151823
[TBL] [Abstract][Full Text] [Related]
17. Fitness Trade-Offs between Phage and Antibiotic Sensitivity in Phage-Resistant Variants: Molecular Action and Insights into Clinical Applications for Phage Therapy.
Fujiki J; Nakamura K; Nakamura T; Iwano H
Int J Mol Sci; 2023 Oct; 24(21):. PubMed ID: 37958612
[TBL] [Abstract][Full Text] [Related]
18. Bacteriophage Treatment Rescues Mice Infected with Multidrug-Resistant Klebsiella pneumoniae ST258.
Hesse S; Malachowa N; Porter AR; Freedman B; Kobayashi SD; Gardner DJ; Scott DP; Adhya S; DeLeo FR
mBio; 2021 Feb; 12(1):. PubMed ID: 33622728
[TBL] [Abstract][Full Text] [Related]
19. Phage Therapy for Respiratory Infections: Opportunities and Challenges.
Khosravi A; Chen Q; Echterhof A; Koff JL; Bollyky PL
Lung; 2024 Jun; 202(3):223-232. PubMed ID: 38772946
[TBL] [Abstract][Full Text] [Related]
20. An exegesis of bacteriophage therapy: An emerging player in the fight against anti-microbial resistance.
Adesanya O; Oduselu T; Akin-Ajani O; Adewumi OM; Ademowo OG
AIMS Microbiol; 2020; 6(3):204-230. PubMed ID: 33134741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
